| Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document M Biegstraaten, R Arngrímsson, F Barbey, L Boks, F Cecchi, PB Deegan, ... Orphanet journal of rare diseases 10, 1-10, 2015 | 354 | 2015 |
| Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry C Wanner, JP Oliveira, A Ortiz, M Mauer, DP Germain, GE Linthorst, ... Clinical Journal of the American Society of Nephrology 5 (12), 2220-2228, 2010 | 201 | 2010 |
| Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation DG Warnock, A Ortiz, M Mauer, GE Linthorst, JP Oliveira, AL Serra, ... Nephrology Dialysis Transplantation 27 (3), 1042-1049, 2012 | 191 | 2012 |
| Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN) AB Fogo, L Bostad, E Svarstad, WJ Cook, S Moll, F Barbey, L Geldenhuys, ... Nephrology Dialysis Transplantation 25 (7), 2168-2177, 2010 | 189 | 2010 |
| Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies Conference R Schiffmann, DA Hughes, GE Linthorst, A Ortiz, E Svarstad, DG Warnock, ... Kidney international 91 (2), 284-293, 2017 | 187 | 2017 |
| End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry A Ortiz, B Cianciaruso, M Cizmarik, DP Germain, R Mignani, JP Oliveira, ... Nephrology Dialysis Transplantation 25 (3), 769-775, 2010 | 159 | 2010 |
| Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy DG Warnock, CP Thomas, B Vujkovac, RC Campbell, J Charrow, ... Journal of medical genetics 52 (12), 860-866, 2015 | 76 | 2015 |
| Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients. M Sabovic, J Lavre, B Vujkovac Nephrology, Dialysis, Transplantation: Official Publication of the European …, 2003 | 54 | 2003 |
| Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialysis patient B Vujkovac, J Lavre, M Sabovic American journal of kidney diseases 31 (3), 536-538, 1998 | 50 | 1998 |
| all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry … AB Fogo, L Bostad, E Svarstad, WJ Cook, S Moll, F Barbey, L Geldenhuys, ... Nephrol Dial Transplant 25 (7), 2168-77, 2010 | 46 | 2010 |
| Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid B Vujkovac, M Šabovič Nephrology Dialysis Transplantation 15 (1), 107-109, 2000 | 44 | 2000 |
| Remarkable variability in renal disease in a large Slovenian family with Fabry disease F Verovnik, D Benko, B Vujkovac, GE Linthorst European journal of human genetics 12 (8), 678-681, 2004 | 43 | 2004 |
| An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease DP Germain, G Altarescu, R Barriales-Villa, R Mignani, K Pawlaczyk, ... Molecular genetics and metabolism 137 (1-2), 49-61, 2022 | 36 | 2022 |
| Evidence for the use of tranexamic acid in subarachnoid and subdural hemorrhage: a systematic review T Anker-Møller, A Troldborg, N Sunde, AM Hvas Seminars in Thrombosis and Hemostasis 43 (07), 750-758, 2017 | 32 | 2017 |
| Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study E Paschke, G Fauler, H Winkler, A Schlagenhauf, B Plecko, W Erwa, ... American journal of kidney diseases 57 (5), 673-681, 2011 | 30 | 2011 |
| Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD … DA Hughes, P Aguiar, PB Deegan, F Ezgu, A Frustaci, O Lidove, A Linhart, ... BMJ open 10 (10), e035182, 2020 | 24 | 2020 |
| Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease L Goláň, O Goker-Alpan, M Holida, I Kantola, M Klopotowski, J Kuusisto, ... Drug Design, Development and Therapy, 3435-3444, 2015 | 23 | 2015 |
| A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid B Vujkovac, M Sabovic Blood coagulation & fibrinolysis 17 (7), 589-591, 2006 | 23 | 2006 |
| Severe diabetic ketoacidosis associated with acute myocardial necrosis M Tretjak, F Verovnik, B Vujkovac, C Slemenik-Pusnik, M Noc Diabetes Care 26 (10), 2959-2960, 2003 | 23 | 2003 |
| Biomarkers of Fabry nephropathy: review and future perspective T Levstek, B Vujkovac, K Trebusak Podkrajsek Genes 11 (9), 1091, 2020 | 20 | 2020 |
